Renal biomarkers are routinely used for early diagnosis and management of kidney diseases. Biomarkers help detect acute renal injuries such as acute kidney injury, chronic kidney disease, or renal tumors at an early stage before the symptoms develop. These biomarkers plays a crucial role in monitoring therapeutic interventions, predicting disease progression, assessing transplant outcomes, and drug toxicity assessments. The global renal biomarkers market involves a variety of tests that measure creatinine, blood urea nitrogen, cystatin C, neutrophil gelatinase-associated lipocalin, and kidney injury molecule 1.
The global renal biomarkers market is estimated to be valued at US$ 1700.59 million in 2024 and is expected to exhibit a CAGR of 3.7% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Early Disease Diagnosis: Biomarkers such as NGAL, KIM-1, IL-18 and L-FABP help detect early signs of renal injuries even before changes occur in serum creatinine levels. Early diagnosis of kidney diseases helps determine appropriate treatments to slow disease progression. This acts as a key driver for the market growth.
Inflammatory Response: Kidney injuries stimulate inflammatory response and expression of proteins that serve as biomarkers. Conditions such as sepsis, cardiovascular surgeries involving cardiopulmonary bypass, and exposure to nephrotoxic drugs can damage renal tubular epithelial cells and induce inflammatory biomarkers release into urine and blood. Increased applications of renal biomarkers in inflammatory response monitoring will support the renal biomarkers market growth during the forecast period.
Segment Analysis
The global renal biomarkers market is dominated by diagnostic segment. Diagnostic segment held more than 60% share of the overall market in 2024 owing to increasing applications of renal biomarkers in diagnosis of acute kidney injury and chronic kidney diseases. The prognostic sub-segment is expected to witness fastest growth during the forecast period due to rising research activities for developing novel renal biomarkers to predict clinical outcomes of kidney diseases.
PEST Analysis
Political: Government initiatives to increase awareness about kidney diseases and support for research & development activities related to diagnosis and treatment of renal disorders is driving the market growth.
Economic: Rising healthcare spending coupled with increasing incidence of lifestyle diseases affecting kidneys such as diabetes and hypertension is fueling the demand for renal biomarkers.
Social: Growing geriatric population susceptible to age-related kidney problems along with increasing focus on early detection and monitoring of kidney damage is propelling the market expansion.
Technological: Continuous innovations in proteomics and genomics for discovery of new biomarkers and development of high-throughput detection platforms are boosting the adoption of renal biomarkers.
Key Takeaways
The Global Renal Biomarkers Market Growth is estimated to be valued at US$ 1700.59 million in 2024 and is expected to exhibit a CAGR of 3.7% over the forecast period 2024 to 2031.
North America dominated the global market in 2024 with over 40% market share owing to presence of major market players and availability of advanced healthcare facilities in the region. The Asia Pacific region is anticipated to be the fastest growing market for renal biomarkers during the forecast period driven by rising prevalence of chronic kidney diseases, increasing healthcare spending, and growth in medical tourism.
Key players operating in the renal biomarkers market are Thermo Fisher Scientific, Abbott Laboratories, BioPorto Diagnostics, Astute Medical, Randox Laboratories, and Biovision. Key players are mainly focusing on new product launches and expanding their geographical presence through strategic collaborations to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it